A cysteine proteinase inhibitor ALLN alleviates bleomycin-induced skin and lung fibrosis

被引:0
|
作者
Kasamatsu, Hiroshi [1 ]
Chino, Takenao [1 ]
Hasegawa, Takumi [1 ]
Utsunomiya, Natsuko [1 ]
Utsunomiya, Akira [1 ]
Yamada, Masami [2 ]
Oyama, Noritaka [1 ]
Hasegawa, Minoru [1 ]
机构
[1] Univ Fukui, Fac Med Sci, Dept Dermatol, Div Med, 23-3 Matsuoka Shimoaizuki, Eiheiji, Fukui 9101193, Japan
[2] Univ Fukui, Fac Med Sci, Dept Cell Biol & Biochem, Div Med, 23-3 Matsuoka Shimoaizuki, Eiheiji, Fukui 9101193, Japan
关键词
Systemic sclerosis; Skin; Lung; Calpain; Cysteine proteinase inhibitor; TGF-& beta; Fibrosis; Endothelial-mesenchymal transition; MESENCHYMAL TRANSITION; SYSTEMIC-SCLEROSIS; DOUBLE-BLIND; CALPAIN; ACTIVATION; EXPRESSION; TGF-BETA-1; CELLS; MODEL;
D O I
10.1186/s13075-023-03130-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Systemic sclerosis (SSc) is a connective tissue disease that is characterized by fibrosis in the skin and internal organs, such as the lungs. Activated differentiation of progenitor cells, which are mainly resident fibroblasts, into myofibroblasts is considered a key mechanism underlying the overproduction of extracellular matrix and the resultant tissue fibrosis in SSc. Calpains are members of theCa(2+)- dependent cysteine protease family, whose enzymatic activities participate in signal transduction and tissue remodeling, potentially contributing to fibrosis in various organs. However, the roles of calpain in the pathogenesis of SSc remain unknown. This study aimed to examine the anti-fibrotic properties of N-acetyl-Leu-Leu-norleucinal (ALLN), one of the cysteine proteinase inhibitors that primarily inhibit calpain, in vitro and in vivo, to optimally translate into the therapeutic utility in human SSc. Methods Normal human dermal and lung fibroblasts pretreated with ALLN were stimulated with recombinant transforming growth factor beta 1 (TGF-beta 1), followed by assessment of TGF-beta 1/Smad signaling and fibrogenic molecules. Results ALLN treatment significantly inhibited TGF-beta 1-induced phosphorylation and nuclear transport of Smad2/3 in skin and lung fibroblasts. TGF-beta 1-dependent increases in a-smooth muscle actin (aSMA), collagen type I, fibronectin 1, and some mesenchymal transcription markers were attenuated by ALLN. Moreover, our findings suggest that ALLN inhibits TGF-beta 1-induced mesenchymal transition in human lung epithelial cells. Consistent with these in vitro findings, administering ALLN (3 mg/kg/day) three times a week intraperitoneally remarkably suppressed the development of skin and lung fibrosis in a SSc mouse model induced by daily subcutaneous bleomycin injection. The number of skin- and lung-infiltrating CD3+ T cells decreased in ALLN-treated mice compared with that in control-treated mice. Phosphorylation of Smad3 and/or an increase in aSMA-positive myofibroblasts was significantly inhibited by ALLN treatment on the skin and lungs. However, no adverse effects were observed. Conclusions Our results prove that calpains can be a novel therapeutic target for skin and lung fibrosis in SSc, considering its inhibitor ALLN.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Pulmonary delivery of nanochelators decreases lung iron accumulation and alleviates bleomycin-induced lung fibrosis in rats
    Patwardhan, Mayuri
    Stiles, Wesley
    Kang, Homan
    Choi, Hak Soo
    Kim, Jonghan
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [32] Skin Progenitor Cells Contribute to Bleomycin-Induced Skin Fibrosis
    Liu, Shangxi
    Herault, Yann
    Pavlovic, Guillaume
    Leask, Andrew
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 (03) : 707 - 713
  • [33] Treatment with chondroitinase ABC alleviates bleomycin-induced pulmonary fibrosis
    Yoshiro Kai
    Hiroyuki Yoneyama
    Jun Koyama
    Kaoru Hamada
    Hiroshi Kimura
    Kouji Matsushima
    Medical Molecular Morphology, 2007, 40 : 128 - 140
  • [34] DNA methyltransferase inhibitor alleviates bleomycin-induced pulmonary inflammation
    Lu, Chun-Hao
    Chen, Chun-Ming
    Ma, Jason
    Wu, Cheng-Jang
    Chen, Li-Chen
    Kuo, Ming-Ling
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 84
  • [35] A critical role of AREG for bleomycin-induced skin fibrosis
    Zhang, Mary Yinghua
    Fang, Shuyi
    Gao, Hongyu
    Zhang, Xiaoli
    Gu, Dongsheng
    Liu, Yunlong
    Wan, Jun
    Xie, Jingwu
    CELL AND BIOSCIENCE, 2021, 11 (01):
  • [36] Fluvoxamine alleviates bleomycin-induced lung fibrosis via regulating the cGAS-STING pathway
    Xie, Xiaohua
    Wu, Xiaofeng
    Zhao, Dongsheng
    Liu, Ying
    Du, Qiyue
    Li, Yitian
    Xu, Yaping
    Li, Yuhang
    Qiu, Yan
    Yang, Yungang
    PHARMACOLOGICAL RESEARCH, 2023, 187
  • [37] Oral Metformin Ameliorates Bleomycin-Induced Skin Fibrosis
    Ursini, Francesco
    Grembiale, Rosa Daniela
    D'Antona, Lucia
    Gallo, Enzo
    D'Angelo, Salvatore
    Citraro, Rita
    Visca, Paolo
    Olivieri, Ignazio
    De Sarro, Giovambattista
    Perrotti, Nicola
    Russo, Emilio
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : 1892 - 1894
  • [38] EHP-101, an oral formulation of the cannabidiol aminoquinone VCE-004.8, alleviates bleomycin-induced skin and lung fibrosis
    Garcia-Martin, Adela
    Garrido-Rodriguez, Martin
    Navarrete, Carmen
    del Rio, Carmen
    Bellido, Maria L.
    Appendino, Giovanni
    Calzado, Marco A.
    Munoz, Eduardo
    BIOCHEMICAL PHARMACOLOGY, 2018, 157 : 304 - 313
  • [39] A critical role of AREG for bleomycin-induced skin fibrosis
    Mary Yinghua Zhang
    Shuyi Fang
    Hongyu Gao
    Xiaoli Zhang
    Dongsheng Gu
    Yunlong Liu
    Jun Wan
    Jingwu Xie
    Cell & Bioscience, 11
  • [40] thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis
    Fujimoto, H
    Gabazza, EC
    Taguchi, O
    Nishii, Y
    Nakahara, H
    Bruno, NE
    D'Alessandro-Gabazza, CN
    Kasper, M
    Yano, Y
    Nagashima, M
    Morser, J
    Broze, GJ
    Suzuki, K
    Adachi, Y
    AMERICAN JOURNAL OF PATHOLOGY, 2006, 168 (04): : 1086 - 1096